NASDAQ: GLPGGalapagos Nv Stock
$29.42-0.34 (-1.14%)
Updated Apr 2, 2026
GLPG Price
$29.42
Fair Value Price
N/A
Market Cap
$1.94B
52 Week Low
$22.59
52 Week High
$37.78
P/E
5.26x
P/B
0.52x
P/S
1.65x
PEG
0.27x
Dividend Yield
N/A
Revenue
$1.28B
Earnings
$377.51M
Gross Margin
97.3%
Operating Margin
27.18%
Profit Margin
28.9%
Debt to Equity
0.05
Operating Cash Flow
-$362M
Beta
0.6
Next Earnings
Apr 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GLPG Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLPG's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GLPG
Ranked#21 of 462
Ranked#21 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $186.95 | A | |
| $16.62 | A | |
| $22.99 | A |
Be the first to know about important GLPG news, forecast changes, insider trades & much more!
GLPG News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLPG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLPG ($29.42) is trading below its intrinsic value of $68.91, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GLPG is good value based on its earnings relative to its share price (5.26x), compared to the US market average (30.13x)
P/E vs Market Valuation
GLPG is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more GLPG due diligence checks available for Premium users.
Valuation
GLPG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.26x
Industry
28.69x
Market
30.13x
GLPG is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GLPG is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
GLPG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
4.77x
GLPG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLPG price to earnings growth (PEG)
For valuing profitable companies with growth potential
GLPG is good value based... subscribe to Premium to read more.
PEG Value Valuation
GLPG's financial health
Profit margin
Revenue
$845.6M
Net Income
$920.2M
Profit Margin
108.8%
GLPG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GLPG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.0B
Liabilities
$200.8M
Debt to equity
0.05
GLPG's short-term assets ($3.54B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLPG's short-term assets ($3.54B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLPG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GLPG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$89.7M
Investing
$85.4M
Financing
-$476.5k
GLPG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLPG vs Biotech Stocks
Galapagos Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.